Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCash from Financing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Dna X (SONM) Share-based Compensation (2018 - 2025)

Historic Share-based Compensation for Dna X (SONM) over the last 8 years, with Q3 2025 value amounting to $166000.0.

  • Dna X's Share-based Compensation fell 5549.6% to $166000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $1.7 million, marking a year-over-year increase of 682.24%. This contributed to the annual value of $1.5 million for FY2024, which is 193.85% up from last year.
  • According to the latest figures from Q3 2025, Dna X's Share-based Compensation is $166000.0, which was down 5549.6% from $926000.0 recorded in Q2 2025.
  • Over the past 5 years, Dna X's Share-based Compensation peaked at $926000.0 during Q2 2025, and registered a low of $166000.0 during Q3 2025.
  • Its 5-year average for Share-based Compensation is $370473.7, with a median of $325000.0 in 2021.
  • Per our database at Business Quant, Dna X's Share-based Compensation soared by 12350.88% in 2022 and then tumbled by 5549.6% in 2025.
  • Dna X's Share-based Compensation (Quarter) stood at $325000.0 in 2021, then rose by 27.69% to $415000.0 in 2022, then grew by 10.36% to $458000.0 in 2023, then dropped by 22.27% to $356000.0 in 2024, then plummeted by 53.37% to $166000.0 in 2025.
  • Its last three reported values are $166000.0 in Q3 2025, $926000.0 for Q2 2025, and $290000.0 during Q1 2025.